Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Protein tyrosine phosphatases (PTPs) are a diverse family of enzymes encoded by 107 genes in the human genome. Together with protein tyrosine kinases (PTKs), PTPs regulate various cellular activities essential for the initiation and maintenance of malignant phenotypes. While PTK inhibitors are now used routinely for cancer treatment, the PTP inhibitor development field is still in the discovery phase. In this article, the suitability of targeting PTPs for novel anticancer drug discovery is discussed. Examples are presented for PTPs that have been targeted for anticancer drug discovery as well as potential new PTP targets for novel anticancer drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249 · cited 1×
“Shp2 is a Class I non-receptor classical Cys-based PTP containing tandem Src homology-2 (SH2) domains [35].”
BackgroundBentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
You, M., Yu, D.-H., & Feng, G.-S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.2416 · Cited by 364 · cited 1×
“Increased IFN-γ-induced responses are observed in mouse embryo fibroblasts lacking Shp2 [64,65].”
BackgroundMolecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
Agazie, Y. M., & Hayman, M. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7875-7886.2003 · Cited by 306
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation
Zhu, S., Bjorge, J. D., & Fujita, D. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4338 · Cited by 168 · cited 1×
“[95] and contributes to tumor growth of SW48 colon cancer cells [96].”
BackgroundMyers, M. G., Mendez, R., Shi, P., Pierce, J. H., Rhoads, R., & White, M. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26908 · Cited by 164
Chan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., & Kapur, R. (2005) · Blood · doi:10.1182/blood-2004-10-4002 · Cited by 156 · cited 1×
“Several laboratories have reported leukemia-associated Shp2 mutants (E76K, D61Y, D61V) are able to confer GM-CSF and IL-3 hypersensitivity of murine hematopoietic progenitor cells from fetal liver or bone marrow and evoked GM-CSFindependent colonies [78-80].”
BackgroundOverexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas
Wiener, J. R., Hurteau, J. A., Kerns, B.-J. M., Whitaker, R. S., Conaway, M. R., Berchuck, A., & Bast, R. C. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(94)70118-0 · Cited by 84 · cited 1×
“PTP1B is overexpressed in breast and ovarian cancer, which correlates with ErbB2 overexpression [99,100].”
Background
Cited by
Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298
Molecular mechanism of SHP2 activation by PD-1 stimulation
Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H. J., Kirkpatrick, J., Rios, P., Schamel, W. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 262
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M. (2015) · Nature Communications · doi:10.1038/ncomms9859 · Cited by 249
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172
Metadata
- Authors
- M. Scott, L., R. Lawrence, H., M. Sebti, S., J. Lawrence, N., & Wu, J.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-06-01
- Volume
- 16
- Issue
- 16
- Pages
- 1843-1862
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2142682969
- Cited by
- 156
- References
- 10
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery. https://app.cochat.ai/papers/10.2174/138161210791209027
- The paper
- M. Scott, L., R. Lawrence, H., M. Sebti, S., J. Lawrence, N., & Wu, J. (2010). Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery. Current Pharmaceutical Design. https://doi.org/10.2174/138161210791209027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.